Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy (original) (raw)

Abstract

In 1996 the prevalence, risk factors, and genotype distribu-subject (0.7%), type 2c in 66 subjects (44.6%), type 3a in 4 subjects (2.7%), and type 4 in two subjects (1.3%). These tion of hepatitis C virus (HCV) infection were assessed in the general population of a town in southern Italy. The sample figures differ from those of Italian patients with chronic liver disease in whom genotype 2 is more rare. None of the individ-was selected from the census by a systematic 1:4 sampling procedure. The participation rate was 96.6%. Among the uals was infected with more than one genotype. The distribution of the two most common HCV viral types (1b and 2c) 1,352 subjects enrolled, 195 (14.4%) tested reactive to antibody to HCV (anti-HCV) with enzyme immunoassay (EIA was not statistically different in terms of mean age, sex, or risk factors and suggests that they may have had a parallel 3). When further tested with recombinant immunoblot assay (RIBA 3), 170 subjects (87.2%) tested positive, 23 subjects spread in this community. These findings provide one of the highest overall anti-HCV prevalence rates in a general popula-(11.8%) had indeterminate results, and 2 subjects (1%) tested negative. Thus, the overall anti-HCV EIA-positive RIBA-con-tion with a likely cohort effect, i.e., decreased risk of infection along generations. These observations may indicate an epi-firmed prevalence was 12.6% (170 of 1,352 subjects) and increased from 1.3% in subjects younger than 30 years to demic or focus of hepatitis C that occurred several years earlier. The majority of anti-HCV-positive subjects in the 33.1% in those ¢60 years of age. This latter age group accounted for 72.3% of all anti-HCV-positive subjects. Females oldest age group and with no clinical evidence suggests that HCV infection is a very prolonged and indolent disease. tested positive more frequently than males (14.1% vs. 10.5%; P õ .05). Alanine transaminase (ALT) concentrations were (HEPATOLOGY 1997;26:1006-1011.) abnormal in only 4.1% (7/170) of anti-HCV EIA-positive RIBA-confirmed subjects. This suggests that ALT screening Hepatitis C virus (HCV) infection represents a major is not useful in the detection of anti-HCV-positive subjects health problem in Italy. It has been found to be highly prevain a general population. The results of multiple logistic regreslent in subjects with chronic liver disease 1-2 and strongly sion analysis showed that an age of less than 45 years, the associated with hepatocellular carcinoma. 3-4 use of glass syringes, and dental therapy were all independent General population surveys in different countries that depredictors of anti-HCV positivity. HCV RNA was detected by termined the prevalence of hepatitis C virus antibodies (antipolymerase chain reaction in 75.9% of the 195 anti-HCV EIA-HCV) have mainly consisted of voluntary or paid blood positive subjects: in 84.7% (144/170) of the RIBA-confirmed donors. Because these populations usually have special charsubjects; in 17.4% (4/23) tested as RIBA indeterminate; and acteristics regarding age, sex, socioeconomic level and selecin neither of the two subjects who tested RIBA negative. HCV tive procedures, they are not representative of the general type 1b was detected in 75 subjects (50.7%), type 2b in 1 population. Few studies using valid sampling procedures have provided reliable figures for anti-HCV prevalence in given areas. 5-12 Abbreviations: HCV, hepatitis C virus; anti-HCV, hepatitis C virus antibodies; HBV, On the basis of the phylogenetic analysis of the viral gehepatitis B virus; ALT, alanine transaminase; RIBA, immunoblot assay; anti-HBc, hepatinome, Okamoto et al. 13 classified HCV into four genotypes. tis B core antigen antibodies; RT-PCR, reverse-transcription polymerase chain reaction; Similarly, Simmonds et al. 14 classified the virus into six major OR, odds ratio; CI, confidence interval. types and a series of subtypes. The characteristics of HCV

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (39)

  1. B virus carriers. J Med Virol 1995;45:367-372. community-based survey. 6 Differences in the age-distribu- 9.
  2. Romano `L, Azara M, Chiaramonte M, De Mattia D, Giammanco A, tion of the populations studied, other than different modes Moschen ME, Scarpa B, et al. Low prevalence of anti-HCV antibody of subject enrollment, may account for the observed discrep- among Italian children. Infection 1994;22:350-352.
  3. D'Amelio R, Stroffolini T, Matricardi PM, Nisini R, Tosti ME, Trematerra ancy in the rate of ALT concentration elevations. M, Villano U, et al. Low prevalence of anti-HCV antibodies among Much of the information on the natural history of HCV Italian Air Force Recruits. Scand J Infect Dis 1995;27:12-14. infection is derived from subjects referred to medical care. 32-34
  4. Bellentani S, Pozzato G, Mazzoran L, Croce `LS, Santini F, Crovatto M, Thus, an obvious referral bias may affect current data. In Barbisin M, et al. HCV genotype distribution in the general population of Northern Italy. J Hepatol 1996;25(S1):145. particular, the natural history of community-acquired disease 12. Stroffolini T, Menchinelli M, Taliani G, Dambruoso V, Poliandri G, is not clear because of the difficulty in defining the onset of Bozza A, Lecce R, et al. High prevalence of hepatitis C virus infection infection and because hepatitis C is often subclinical. How- in a small central Italian town: lack of evidence of parenteral exposure. ever, hepatitis C is considered to have a progressive course Ital J Gastroenterol 1995;27:235-238.
  5. to chronic disease occurring over decades, during which time 13. Okamoto H, Sugiyama H, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al. Typing hepatitis C virus by polymerase chain reaction with the individual may be symptom-free. Thus, the disease may type-specific primers: application to clinical surveys and tracing infec- remain undiagnosed until the patient presents with liver dis- tion sources. J Gen Virol 1992;73:673-679.
  6. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, cases the disease may run a prolonged, indolent course with Beall E, et al. Classification of hepatitis C virus into six major genoptypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J no clinical consequences. Death from liver disease occurred Gen Virol 1993;74:2391-2399.
  7. in only 3.3% of 568 patients followed up for an average of 15. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sher- 18 years after an episode of transfusion-associated non-A, lock S, McIntyre N, et al. Hepatitis C virus genotypes: an investigation non-B hepatitis compared with 1.5% of a control group of of type specific differences in geographic origin and disease. HEPATOL- 984 patients who had transfusions and did not develop hepa- OGY 1994;19:13-18.
  8. Nousbaum JP, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. titis. 35 Moreover, the life expectancy of compensated cirrho- Hepatitis C virus type 1b infection in France and Italy. Ann Intern Med sis hepatitis C is relatively long in most patients (91% sur- 1995;122:161-168.
  9. vival probability at 5 years; 79% at 10 years) as recently 17. Rumi MG, Iacano OL, Mingall SA, Bernhardt XF, Chemello L, Civeira shown in a Western European study. 36 MP, Christofer F, et al. Epidemiological, clinical and therapeutic associ- ations of hepatitis C types in Western European patients. J Hepatol We are aware that the findings of this community-based 1996;24:517-524.
  10. Pontisso P, Ruvoletto MG, Nicoletti M, Tisminetzk YS, Gerotto M, is the potential for survival bias because this was a cross- Levrero M, Artini M, et al. Distribution of three major hepatitis C virus sectional study. However, the high proportion of elderly anti- genotypes in Italy. A multicenter study of 495 patients with chronic HCV-positive subjects without clinical symptoms observed heptaitis C. J Viral Hepat 1995;2:33-38.
  11. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G. in this community suggests that HCV infection is a disease Differential distribution of hepatitis C virus genotypes in patients with that is less aggressive than is currently thought. These data and without liver function abnormalities. HEPATOLOGY 1995;21:285- should be taken into account to fully delineate the natural 290. history of HCV infection.
  12. McOmish F, Yap P, Dow BC, Follett EAC, Seed C, Keller A, Cobain TJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol REFERENCES 1994;32:884-892.
  13. Shev S, Widell A, Foberg U, Fryden A, Hermodsson S, Lindh G, Lind-
  14. Chiaramonte M, Stroffolini T, Caporaso N, Coppola R, CraxıD A, Gaeta holm A, et al. HCV genotypes in Swedish blood donors as correlated GB, Sagnelli E, et al. Hepatitis C virus infection in Italy. Ital J Gastroent- to epidemiology, liver disease and hepatitis C virus antibody profile. erol 1991;23:555-558. Infection 1995;23:253-257.
  15. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic 22. Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M, Zanuso factors in cirrhosis with and without hepatocellular carcinoma: a F, et al. Influence of different hepatitis C virus genotypes on the course multicenter Italian study. HEPATOLOGY 1994;20:1442-1449. of asymptomatic hepatitis C virus infection. Gastroenterology 1996;
  16. Simonetti RG, Camma `C, Fiorello F, Cottone M, Rapicetta M, Marino 110:178-183.
  17. L, Fiorentino G, et al. Hepatitis C virus infection as a risk factor for 23. Abramson JH: Survey methods in community medicine. New York, hepatocellular carcinoma in patients with cirrhosis. A case-control Churchill Livingstone, 1983:25-28. study. Ann Intern Med 1992;116:97-102.
  18. Okamoto H, Tokita M, Sakamoto M, Horikita M, Iizuka H, Mishiro S.
  19. Stroffolini T, Chiaramonte M, Tiribelli C, Villa E, Simonetti R, Rapicetta Characterization of the genomic sequence of type V (or 3a) hepatitis
  20. M, Stazi MA, et al. Hepatitis C virus infection, HBsAg carrier state and C virus isolates and PCR primers for specific detection. J Gen Virol hepatocellular carcinoma: Relative risk and population attributable risk 1993;74:2385-2390. from a case-control study in Italy. J Hepatol 1992;16:360-363.
  21. Spada E, Ciccaglione AR, Dettori S, Chionne P, Kondili L, Rapicetta M.
  22. AlFaleh FZ, Ayoola EA, Aljeffry M, Alrashed R, Almofareh M, Arif M, HCV genotyping in the core region: an optimization of multiple PCR. IX
  23. Ramia S, et al. Prevalence of antibody to hepatitis C virus among Saudi Triennial International Symposium on Viral Hepatitis and Liver Disease Arabian children: a community based study. HEPATOLOGY 1991;14:215- 1996:246(Abstract C171).
  24. 26. Klinbaum DG, Kupper LL, Chambless LE. Logistic regression analysis
  25. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, Perez-Flores D, Chirlaque of epidemiological data. Theory and practice. Commun Statist Theory D, Navarro C. Prevalence of hepatitis B and C markers in the south- Methods 1982;71:485-547.
  26. east of Spain: a community based serosurvey of 2,203 adults. Scand J 27. Kahn HA, Sempos CT. Statistical methods in epidemiology. New York, Infect Dis 1996;28:17-20. NY: Oxford University, 1989:506-558.
  27. Xia GL, Liu CB, Cao HL, Bi SL, Zhan MV, Su CA, Nan JH. Prevalence 28. Chiaramonte M, Stroffolini T, Lorenzoni V, Minniti F, Conti S, Floreani, of hepatitis B and C virus infections in the general Chinese population.
  28. Ntakirutimana E, et al. Risk factors in community acquired hepatitis C Results from a nationwide cross sectional seroepidemiologic study of virus chronic infection: A case control study in Italy. J Hepatol 1996;
  29. A,B,C,D, and E virus infections in China, 1992. Int Hepatol 24:129-134. Commun 1993;74:2385-2390.
  30. Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tinelli C, Bruno
  31. Tawaraya H, Ohkoshi S, Kuwana K, Watanabe M, Kamimura T, Asakura S, et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J Hepatol 1995;22:691-695.
  32. H. Epidemiologic survey and genetic analysis of endemic hepatitis C
  33. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval 33. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after trans- fusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
  34. J, Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 34. Alter MJ, Margolis HS, Krawczynski , Judson FN, Mares A, Alexander W J, Hu PA, et al. The natural history of community-acquired hepatitis 1995;11:1607-1610.
  35. Kaur S, Rybcki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Perfor- C in the United States. N Engl J Med, 1992;327:1899-1905.
  36. Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HI, Iber FL, mance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
  37. B and C: Results of the National Hepatitis Screening Survey. HEPATOL- OGY 1996;24:979-986.
  38. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type
  39. DiBisceglie AM, Goddman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472. post-transfusion hepatitis. HEPATOLOGY 1991;14:969-974.